Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Reduced Dose Fludarabine/Cyclophosphamide Lymphodepletion Before Tumor-Infiltrating Lymphocyte Therapy With Lifileucel in Metastatic Melanoma

NCT06151847 is registered in ClinicalTrials.gov with University of Kansas Medical Center as lead sponsor.

NCT NCT06151847
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06151847 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Reduced Dose Fludarabine/Cyclophosphamide Lymphodepletion Before Tumor-Infiltrating Lymphocyte Therapy With Lifileucel in Metastatic Melanoma
Lead sponsor
University of Kansas Medical Center
Phase
Phase 2
Overall status
Completed
Start date
December 21, 2023
Completion date
July 10, 2025
Enrollment
11 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

clinical stage iv cutaneous melanoma ajcc v8, metastatic melanoma, pathologic stage iiic cutaneous melanoma ajcc v8, unresectable melanoma